Home > Blogs > Prostate Cancer Awareness Month: The Emerging Role of Genomic Testing in Precision Oncology

Prostate Cancer Awareness Month: The Emerging Role of Genomic Testing in Precision Oncology

Understanding inherited cancer risk, tumor genetics, and the future of personalized prostate cancer care

Understanding Prostate Cancer Beyond Diagnosis

Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Although many cases grow slowly, others can be aggressive, spread to distant organs, or recur following treatment.

Understanding the biological differences between tumors is essential to improving cancer assessment and management. Age, family history, and inherited genetic variations can all influence prostate cancer risk. Advances in genomic testing are creating new opportunities to investigate these factors and support precision oncology. [1]

Understanding the Genetic Basis of Prostate Cancer

Prostate cancer can develop through a combination of inherited genetic susceptibility and acquired alterations within tumor cells. Several genes are particularly relevant to hereditary prostate cancer:

BRCA1 and BRCA2: Involved in DNA repair; inherited pathogenic variants, particularly in BRCA2, are associated with increased prostate cancer risk.
ATM: Plays an important role in the cellular response to DNA damage.
HOXB13: Certain inherited variants are associated with hereditary prostate cancer susceptibility.
Mismatch repair genes: Including MLH1, MSH2, MSH6, and PMS2, which help maintain genomic stability.

Identifying clinically significant inherited variants may help clarify cancer risk, support genetic counselling, and inform clinical management. Some findings may also have implications for eligible family members. [2]

What Can Genomic Testing Reveal About Prostate Cancer?

Depending on the sample type and assay design, genomic testing can provide insights into inherited cancer risk and tumor biology. Its applications include identifying hereditary variants, characterizing tumor alterations, and detecting biomarkers that may be relevant to targeted treatment decisions. [3]

Two complementary approaches are particularly important:

Germline genetic testing analyzes DNA, usually from blood, to identify inherited variants associated with cancer susceptibility. These findings may also have implications for family members.
Somatic tumor profiling: investigates acquired genetic alterations in tumor tissue or, in selected settings, circulating tumor DNA (ctDNA) from blood. In advanced prostate cancer, alterations involving DNA repair pathways and mismatch repair deficiency may provide information relevant to treatment selection. [2]

Although both approaches contribute to precision oncology, they answer different clinical questions and should not be considered interchangeable.

DNA GTx: Connecting Genomic Testing with Precision Oncology

At DNA GTx, we recognize the growing importance of genomic testing in understanding cancer at the molecular level. Our portfolio includes approaches designed to investigate inherited cancer susceptibility and tumor-associated genetic alterations.

Relevant testing solutions include:

BRCA Panels: Investigating BRCA1 and BRCA2 alterations relevant to hereditary cancer risk and selected treatment assessments.
Hereditary Cancer Panel: Evaluating multiple genes associated with inherited cancer susceptibility.
OncoReveal Panel: Supporting tumor molecular profiling through the detection of cancer-associated genetic alterations.
GTx200/500: Genomic profiling solutions designed to investigate cancer-associated molecular alterations, according to panel configuration and intended use.
Together, these approaches illustrate how germline testing and tumor profiling can provide complementary information about inherited susceptibility and tumor biology [4].

The Future of Genomic Testing in Prostate Cancer

Advances in genomic testing are expanding opportunities to identify inherited cancer-associated variants, characterize tumor alterations, and investigate biomarkers relevant to targeted therapies.

As research progresses, integrating genomic information into appropriate clinical assessment may contribute to more individualized approaches to prostate cancer management.

At DNA GTx, we remain committed to advancing genomic science and supporting the evolving role of molecular testing in precision oncology.

DNA GTx _ Connecting Genomics and Precision Oncology

Clinical note: Germline and somatic testing should be considered according to clinical guidelines, personal and family history, and disease characteristics. Results should be interpreted by qualified healthcare professionals. Genomic testing does not replace PSA assessment, imaging, biopsy, or standard clinical follow-up

📚 References

1. National Cancer Institute. Genetics of Prostate Cancer (PDQ®)–Health Professional Version.
2. Vietri, Maria Teresa, Giovanna D’elia, Gemma Caliendo, Marianna Resse, Amelia Casamassimi, Luana Passariello, Luisa Albanese, Michele Cioffi, and Anna Maria Molinari. “Hereditary prostate cancer: genes related, target therapy and prevention.” International journal of molecular sciences 22, no. 7 (2021): 3753.
3. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. National Comprehensive Cancer Network.
4. George, Angela, Stan Kaye, and Susana Banerjee. “Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.” Nature reviews Clinical oncology 14, no. 5 (2017): 284-296.

Socials